TET2 and myelodysplastic syndrome: Interestingly, this high sensitivity to hypomethylating agents could be linked to the specific pattern of mutation more frequently observed in MDS patients with SIAD (TET2/IDH in 59% vs. 38% of patients with or without SIAD, respectively) and the better response to HMA observed in patients with a TET2 mutation [10].